Radiomics and Artificial Intelligence in Uterine Sarcomas: A Systematic Review.

artificial intelligence deep learning fibroids machine learning radiomics uterine sarcoma uterine tumors

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
11 Nov 2021
Historique:
received: 20 08 2021
revised: 28 10 2021
accepted: 09 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

Recently, artificial intelligence (AI) with computerized imaging analysis is attracting the attention of clinicians, in particular for its potential applications in improving cancer diagnosis. This review aims to investigate the contribution of radiomics and AI on the radiological preoperative assessment of patients with uterine sarcomas (USs). Our literature review involved a systematic search conducted in the last ten years about diagnosis, staging and treatments with radiomics and AI in USs. The protocol was drafted according to the systematic review and meta-analysis preferred reporting project (PRISMA-P) and was registered in the PROSPERO database (CRD42021253535). The initial search identified 754 articles; of these, six papers responded to the characteristics required for the revision and were included in the final analysis. The predominant technique tested was magnetic resonance imaging. The analyzed studies revealed that even though sometimes complex models included AI-related algorithms, they are still too complex for translation into clinical practice. Furthermore, since these results are extracted by retrospective series and do not include external validations, currently it is hard to predict the chances of their application in different study groups. To date, insufficient evidence supports the benefit of radiomics in USs. Nevertheless, this field is promising but the quality of studies should be a priority in these new technologies.

Sections du résumé

BACKGROUND BACKGROUND
Recently, artificial intelligence (AI) with computerized imaging analysis is attracting the attention of clinicians, in particular for its potential applications in improving cancer diagnosis. This review aims to investigate the contribution of radiomics and AI on the radiological preoperative assessment of patients with uterine sarcomas (USs).
METHODS METHODS
Our literature review involved a systematic search conducted in the last ten years about diagnosis, staging and treatments with radiomics and AI in USs. The protocol was drafted according to the systematic review and meta-analysis preferred reporting project (PRISMA-P) and was registered in the PROSPERO database (CRD42021253535).
RESULTS RESULTS
The initial search identified 754 articles; of these, six papers responded to the characteristics required for the revision and were included in the final analysis. The predominant technique tested was magnetic resonance imaging. The analyzed studies revealed that even though sometimes complex models included AI-related algorithms, they are still too complex for translation into clinical practice. Furthermore, since these results are extracted by retrospective series and do not include external validations, currently it is hard to predict the chances of their application in different study groups.
CONCLUSION CONCLUSIONS
To date, insufficient evidence supports the benefit of radiomics in USs. Nevertheless, this field is promising but the quality of studies should be a priority in these new technologies.

Identifiants

pubmed: 34834531
pii: jpm11111179
doi: 10.3390/jpm11111179
pmc: PMC8624692
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Fondazione Cassa di Risparmio in Bologna
ID : to AMP

Références

Eur J Surg Oncol. 2021 Nov;47(11):2734-2741
pubmed: 34183201
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Clin Radiol. 2019 Feb;74(2):167.e1-167.e7
pubmed: 30471748
Cancer Cell. 2021 Jul 12;39(7):916-927
pubmed: 33930310
J Obstet Gynaecol. 2021 Apr;41(3):414-420
pubmed: 32347768
J Card Surg. 2021 Nov;36(11):4121-4124
pubmed: 34392567
Int J Mol Sci. 2020 Sep 29;21(19):
pubmed: 33003368
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751892
Acad Radiol. 2019 Oct;26(10):1390-1399
pubmed: 30661978
Cancers (Basel). 2021 Feb 25;13(5):
pubmed: 33668727
Mol Imaging Biol. 2019 Dec;21(6):1157-1164
pubmed: 30850967
Int J Gynecol Cancer. 2019 Sep;29(7):1134-1140
pubmed: 31420411
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Nat Rev Drug Discov. 2010 May;9(5):363-6
pubmed: 20431568
Ultrasound Obstet Gynecol. 2019 Nov;54(5):676-687
pubmed: 30908820
Med Ref Serv Q. 2019 Apr-Jun;38(2):171-180
pubmed: 31173570
Eur J Radiol. 2019 Jan;110:203-211
pubmed: 30599861
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Sci Rep. 2020 May 4;10(1):7404
pubmed: 32366933
Eur J Radiol. 2019 Jun;115:39-45
pubmed: 31084757
Oncotarget. 2019 Apr 2;10(26):2561-2575
pubmed: 31069017
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401

Auteurs

Gloria Ravegnini (G)

Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.

Martina Ferioli (M)

Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.

Alessio Giuseppe Morganti (AG)

Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.

Lidia Strigari (L)

Medical Physics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Maria Abbondanza Pantaleo (MA)

Division of Oncology, IRCCS-Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.

Margherita Nannini (M)

Division of Oncology, IRCCS-Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.

Antonio De Leo (A)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.

Eugenia De Crescenzo (E)

Division of Oncologic Gynecology, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences (DIMEC)-Centro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR), University of Bologna, 40138 Bologna, Italy.

Manuela Coe (M)

Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Alessandra De Palma (A)

Forensic Medicine and Integrated Risk Management Unit, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.

Pierandrea De Iaco (P)

Division of Oncologic Gynecology, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences (DIMEC)-Centro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR), University of Bologna, 40138 Bologna, Italy.

Stefania Rizzo (S)

Istituto di Imaging della Svizzera Italiana (IIMSI), Ente Ospedaliero Cantonale (EOC), Via Tesserete 46, 6900 Lugano, Switzerland.
Facoltà di Scienze biomediche, Università della Svizzera italiana (USI), via Buffi 13, 6900 Lugano, Switzerland.

Anna Myriam Perrone (AM)

Division of Oncologic Gynecology, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences (DIMEC)-Centro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR), University of Bologna, 40138 Bologna, Italy.

Classifications MeSH